GoodCell (LifeVault Bio), the company decoding human health to extend and improve the quality of life through technology powered by science, has announced that it has raised US$17.9 million in a preferred equity financing round. GoodCell intends to use this latest funding to continue the development of its technology for detecting and monitoring accumulated genetic variation within blood cells. The financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and its personal biobanking service.
Latham & Watkins LLP represented GoodCell in the transaction with a Boston-based corporate deal team led by partner John Chory and associates Spencer Ricks and Belinda King.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
